Hydrocortisone plus Fludrocortisone for Adults with Septic Shock
Source: View publication →
In adults with septic shock, the combination of hydrocortisone and fludrocortisone reduced 90-day all-cause mortality compared with placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
APROCCHSS demonstrated that providing stress-dose hydrocortisone alongside fludrocortisone safely improves 90-day survival and hastens shock reversal in patients with vasopressor-dependent septic shock. Published alongside the ADRENAL trial, it established the role of corticosteroids in resolving persistent vasoplegia and improving clinical trajectories in severe distributive shock, heavily influencing modern Surviving Sepsis Campaign guidelines.
Historical Context
The utility of corticosteroids in sepsis had been debated for decades. High-dose steroids failed in the 1980s, but the 2002 trial by Annane et al. suggested a mortality benefit for low-dose steroids in nonresponders to corticotropin. This was heavily challenged by the 2008 CORTICUS trial which found no survival benefit. APROCCHSS was designed to definitively resolve the debate for high-risk patients. Its 2018 publication, along with the ADRENAL trial (which used hydrocortisone alone and found no mortality benefit but showed faster shock resolution), provided robust evidence that steroids shorten shock duration and may offer a distinct mortality benefit when used with a mineralocorticoid in severely ill populations.
Guided Discussion
High-yield insights from every perspective
Physiologically, why might the addition of fludrocortisone to hydrocortisone provide a synergistic benefit in stabilizing blood pressure in a patient with septic shock?
Key Response
Hydrocortisone acts primarily as a glucocorticoid to modulate the inflammatory response and restore vascular sensitivity to catecholamines, with only mild mineralocorticoid activity. Fludrocortisone provides potent mineralocorticoid effects, promoting sodium and water retention in the distal renal tubule to increase intravascular volume, thus directly countering the profound capillary leak and vasoplegia characteristic of septic shock.
In a patient with refractory septic shock requiring escalating doses of norepinephrine, what are the specific criteria to initiate corticosteroid therapy, and how do the APROCCHSS trial results influence your choice of specific agents?
Key Response
Surviving Sepsis Campaign guidelines suggest initiating IV corticosteroids if adequate fluid resuscitation and vasopressor therapy (typically norepinephrine > 0.25 mcg/kg/min for at least 4 hours) fail to restore hemodynamic stability. While many centers traditionally relied on hydrocortisone alone, APROCCHSS demonstrated a 90-day mortality benefit with the combination of hydrocortisone and fludrocortisone, prompting a shift toward dual therapy in highly refractory cases.
How do you reconcile the conflicting 90-day mortality outcomes between the APROCCHSS trial, which showed a significant benefit with dual corticosteroid therapy, and the ADRENAL trial, which showed no mortality benefit with continuous hydrocortisone alone?
Key Response
Discrepancies likely arise from multiple methodological and clinical differences: APROCCHSS included fludrocortisone (providing extra mineralocorticoid effect) and used bolus dosing of hydrocortisone, whereas ADRENAL used continuous hydrocortisone without fludrocortisone. Additionally, APROCCHSS enrolled a sicker cohort with higher baseline mortality, suggesting that the mortality benefit of steroids in sepsis may be restricted to the most severely ill subset of patients.
Given the APROCCHSS trial results, how do you balance the observed mortality benefit of adding fludrocortisone to hydrocortisone against the risks of corticosteroid-induced complications, such as ICU-acquired weakness and hyperglycemia, particularly in frail patients?
Key Response
Attending decision-making requires weighing the Number Needed to Treat (NNT) for mortality against the Number Needed to Harm (NNH) for adverse events. Although APROCCHSS did not find a statistically significant increase in major secondary infections or critical illness polyneuropathy, hyperglycemia was common. The key is strict glycemic monitoring and prompt de-escalation of steroids once vasopressors are weaned, recognizing that surviving the initial profound shock outweighs the generally reversible metabolic adverse effects.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The APROCCHSS trial originally utilized a 2x2 factorial design that included drotrecogin alfa (activated), which was abruptly withdrawn from the market midway through the study. Methodologically, how does suspending one arm of a factorial design impact statistical power, and how must investigators adjust their analysis to preserve trial integrity?
Key Response
Withdrawing an intervention in a factorial design significantly threatens statistical power, especially if the original sample size relied on testing interaction effects between the two therapies. Investigators must ensure the remaining assignments (steroids vs. placebo) remain balanced across the pre- and post-withdrawal periods, often requiring stratified analyses by enrollment period and potentially increasing the total sample size or trial duration to maintain adequate power for the remaining primary outcome.
As a peer reviewer, how would you evaluate the impact of the APROCCHSS trial's exceptionally long enrollment period (nearly 10 years) on the external validity of its findings, considering the rapid evolution of sepsis standard-of-care during that time?
Key Response
A decade-long enrollment introduces significant temporal bias. Over those 10 years, sepsis definitions changed (Sepsis-2 to Sepsis-3), Early Goal-Directed Therapy (EGDT) was largely abandoned, and antibiotic stewardship protocols evolved. A rigorous reviewer would scrutinize whether the mortality benefit observed in patients enrolled early in the trial remains applicable to cohorts treated under contemporary, highly protocolized sepsis bundles.
The Surviving Sepsis Campaign (SSC) guidelines issue a weak recommendation for IV corticosteroids in refractory septic shock. Based on the APROCCHSS and ADRENAL data, should the SSC guidelines specifically mandate the addition of fludrocortisone to hydrocortisone, and how would you grade the quality of this evidence?
Key Response
While APROCCHSS demonstrated a mortality benefit with the hydrocortisone-fludrocortisone combination, the larger ADRENAL trial showed no mortality benefit with hydrocortisone alone, and there is no definitive head-to-head trial comparing hydrocortisone alone versus the combination. Consequently, a guideline committee would likely maintain a weak recommendation (moderate quality of evidence) for corticosteroids overall, but add a specific, graded suggestion favoring the combination therapy based on the APROCCHSS mortality data and the low cost/risk profile of fludrocortisone.
Clinical Landscape
Noteworthy Related Trials
Annane et al. Sepsis Trial
Tested
Hydrocortisone (50mg IV q6h) plus Fludrocortisone (50 micrograms daily)
Population
Adults with septic shock
Comparator
Placebo
Endpoint
28-day mortality in corticotropin nonresponders
CORTICUS Trial
Tested
Hydrocortisone (50mg IV every 6 hours)
Population
Adults with severe sepsis and septic shock
Comparator
Placebo
Endpoint
28-day mortality in nonresponders to corticotropin
ADRENAL Trial
Tested
Hydrocortisone continuous infusion (200mg/day)
Population
Adults with septic shock undergoing mechanical ventilation
Comparator
Placebo
Endpoint
90-day all-cause mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis